Cardiomyopathies et péricardite
JESFC 2025

Ca avance dans l'amylose

Publié le vendredi 17 janvier 2025

Modérateur(s) :

Vincent Algalarrondo , Olivier Lairez

Orateur(s) :

Thibaud Damy , Camille Jean , Raphaël Mirailles , Mounira Kharoubi , Sabina Istratoaie , Michel Slama

Dans la session

Olivier Lairez Long-term effects of patisiran on survival and cardiac parameters in patients with transthyretin-mediated cardiac amyloidosis: Post hoc analysis of...
Thibaud Damy Outpatient Heart Failure Worsening In Patients With Cardiac Transthyretin Amyloidosis: Results From The Apollo-B Trial
Camille Jean Impact of high intensity and long duration exercise in genetic arrhythmogenic left ventricular cardiomyopathy
Raphaël Mirailles Machine learning score using multiparametric assessment for death prediction in cardiac amyloidosis
Mounira Kharoubi The Healthcare Amyloidosis European Registry (HEAR): study design and methods
Sabina Istratoaie Incidence and predictors for pacemaker implantation in transthyretin cardiac amyloidosis
Michel Slama ATTR Cardiomyopathy in Early and Late onset ATTRV30M
Olivier Lairez Exploratory Analyses from HELIOS-B, a Phase 3 Study of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

Partager l'article :